IP Library › Granted Patent US 8,574,574
Granted Patent B2
US 8,574,574 · App. 12/879,121 · Granted Nov 5, 2013

Pharmaceutical composition comprising antibody composition which specifically binds to CCR4

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,574,574
App. No.
12/879,121
Granted
Nov 5, 2013
Kind
B2
Abstract

A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.

Claims (6)

1. A method for treating cutaneous T cell lymphoma, comprising administering a recombinant antibody which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and Lenalidomide, wherein said recombinant antibody comprises complementarity determining region (CDR) 1, CDR2 and CDR3 of an antibody heavy chain variable region which comprise the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and CDR1, CDR2 and CDR3 of an antibody light chain variable region which comprise the amino acid sequences of SEQ ID NOs: 8, 9 and 10, respectively.

2. The method according to claim 1 , which comprises simultaneously or sequentially administering the recombinant antibody and Lenalidomide.

3. The method according to claim 1 , wherein the tumor is a tumor which expresses CCR4.

4. The method according to claim 1 , wherein the recombinant antibody is an antibody having a high antibody-dependent cellular cytotoxicity.

5. The method according to claim 1 , wherein the recombinant antibody is a humanized antibody.

6. The method according to claim 5 , wherein, in the humanized antibody, the heavy chain variable region of the antibody molecule comprises the amino acid sequence of SEQ ID NO:11, and the light chain variable region of the antibody molecule comprises the amino acid sequence of SEQ ID NO:12.

Assignments (1)
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →